SCHEMBL5564217

SCHEMBL5564217

CC(=O)c1ccc(S(=O)(=O)NC(C)(C)C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.55
CA9 Q16790 2/20 0.55
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
ALDH1A1 P00352 4/20 0.54
MAPT P10636 3/20 0.54
HPGD P15428 2/20 0.50
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CYP19A1 P11511 1/20 0.47
LMNA P02545 4/20 0.44
ALOX12 P18054 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
THRB P10828 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643243 0.84 ALDH1A1 (0.58) CA12CA9KMT2AMEN1ALDH1A1
SCHEMBL14676354 0.84 MEN1 (0.51) CA12CA9KMT2AMEN1ALDH1A1
SCHEMBL3392200 0.83 ALDH1A1 (0.54) CA12CA9KMT2AMEN1ALDH1A1
SCHEMBL10402270 0.82 BCAT1 (0.50) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL14676357 0.81 CA12 (0.50) CA12CA9KMT2AMEN1ALDH1A1
SCHEMBL14676570 0.81 MMP2 (0.52) CA12CA9CA1CA2L3MBTL1
SCHEMBL14676363 0.81 MMP2 (0.52) ALDH1A1SLC1A3SLC1A2SLC1A1CA1
SCHEMBL14676210 0.81 MMP1 (0.61) ALDH1A1SLC1A3SLC1A2SLC1A1CA1
SCHEMBL14676772 0.81 ALDH1A1 (0.58) KMT2AMEN1ALDH1A1MAPTSLC1A2
SCHEMBL14675960 0.80 ADAMTS4 (0.54) CA12CA9KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073830-B2 Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same HYUNDAI PHARM CO., LTD. (KR) 2015-07-07 US disclosed
US-9073830-B2 Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same HYUNDAI PHARM CO., LTD. (KR) 2015-07-07 US disclosed
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2014-07-24 US disclosed
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2014-07-24 US disclosed
WO-2013019091-A2 A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-02-07 WO disclosed
WO-2013019091-A2 A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-02-07 WO disclosed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HSD11B1, HSD11B2, HSD17B1 CA12 2350/4885CA9 908/4885KMT2A 3361/4885
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CA12 1535/4885CA9 1619/4885KMT2A 3609/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CA12 1535/4885CA9 1619/4885KMT2A 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.